A

Aignostics

www.aignostics.com link_icon

Company Market Research Report: Aignostics GmbH



Company Overview



Name: Aignostics GmbH

Mission: To transform drug development and improve patient outcomes with offerings that deliver novel insights for precision medicine.

Founded: Established in 2018 within the walls of Charité Berlin and the Berlin Institute of Health, officially spun out in 2020.

Founders: Aignostics is a spin-off from Charité Berlin, with co-founders including Viktor Matyas, Maximilian Alber, Prof. Frederick Klauschen, and Prof. Klaus-Robert Müller.

Key People:
  • Viktor Matyas, MBA, Co-Founder & CEO

  • Maximilian Alber, PhD, Co-Founder & CTO

  • Todd Dembo, PhD, VP Business Development

  • Rosemarie Krupar, MD, PhD, VP of Pathology

  • Lukas Ruff, PhD, VP of Data Science

  • Verena Aumiller, PhD, VP of Scientific Programs

  • Marija Pezer, PhD, Head of Translational Programs


Headquarters: Berlin, with additional offices in New York

Number of Employees: Over 100 cross-functional experts

Revenue: No information is available

Known For: Leading in AI-powered precision medicine, focusing on computational pathology for pharmaceutical research, clinical trials, and companion diagnostics development.

Products



1. Target Identification


  • Description: Leverages multimodal AI and proprietary datasets to identify novel targets for biopharma.

  • Key Features:

  • Utilizes bespoke multi-modal data generation

  • Employs integrated machine learning algorithms for target identification


2. Translational Research


  • Description: Analyzes complex imaging and omics data reliably and at scale for preclinical development.

  • Key Features:

  • Machine learning for novel, complex signal detection

  • Suite of translational research applications including Tissue QC, Cell detection, and Tissue segmentation


3. Trials & Companion Diagnostics


  • Description: Develops regulatory-grade algorithms that streamline scoring of biomarkers for clinical trials and companion diagnostics (CDx).

  • Key Features:

  • GCP-compliant biomarker scoring in clinical trials

  • Interim analyses for ongoing clinical trials


Foundation Model: RudolfV


  • Description: A foundation model developed using a “pathologist-in-the-loop” approach, enhancing model robustness for histopathology.

  • Key Features:

  • Over 90% accuracy on key histopathology benchmarks

  • Up to 90% less training data needed for new models


Recent Developments



  • December 2023: Aignostics announced its foundation model RudolfV achieved higher accuracy compared to published alternatives on key public datasets. The model will be utilized across all histopathology-related client work.


  • March 14, 2024: Announced a strategic collaboration with Bayer to co-develop a novel target identification platform for precision oncology, leveraging AI and multimodal patient data.


  • October 20, 2023: Achieved ISO 13485 certification for clinical research and diagnostics development, underscoring commitment to regulatory and operational excellence.


  • January 9, 2024: The foundation model RudolfV took the lead on key benchmarks, significantly improving scalabilities and performance for various tasks in histopathology.


Partnerships



  • Bayer Collaboration (March 2024): Multi-year research collaboration to identify novel cancer targets through AI models applied to multimodal patient data, aiming to accelerate clinical development in oncology.


  • Ultivue Partnership (March 2022): Co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research, leveraging multiplex immunofluorescence (mIF) capabilities.


Certifications



  • ISO 13485: Certification for quality management system in the design, development, manufacturing, and distribution of software as a medical device.


  • ISO/IEC 27001: Certification for Information Security Management System, highlighting a commitment to information security and data protection.


Funding and Investment



  • Raised over $20 million in funding from blue-chip investors.

  • Has established partnerships for research and development, as well as capital investment.


This comprehensive report captures the essence and recent milestones of Aignostics GmbH, a company at the forefront of leveraging AI technologies and precision diagnostics to enhance patient outcomes.